Actualités Eyegate Pharmaceuticals Inc - EYEGW | Actions NASDAQ

EyeGate Pharmaceuticals to Present at the 2016 Aegis Capital Conference

WALTHAM, Mass., Sept. 21, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (Nasdaq:EYEG), (“EyeGate”...

EyeGate Awarded $448,185 for second year of funding of Phase II SBIR Grant from U.S. Department of Defense

WALTHAM, Mass., Sept. 13, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate”...

EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437

WALTHAM, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate”...

EyeGate Pharmaceuticals to Present at the 18th Annual Rodman and Renshaw Global Investment Conference

WALTHAM, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- EYEG (Nasdaq:EYEG), (“EyeGate” or the “Company”...

EyeGate Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update

WALTHAM, Mass., Aug. 10, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate”...

EyeGate Announces Positive Top-line Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Post-Operative Inflammat...

WALTHAM, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate”...

EyeGate Announces Completion of $3.77 Million Registered Direct Offering

WALTHAM, Mass., June 30, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate”...

EyeGate Announces $3.77 Million Registered Direct Offering

WALTHAM, Mass., June 27, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate”...

EyeGate Announces Encouraging Interim Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Ocular Inflammation an...

WALTHAM, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate”...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Eyegate Pharmaceuticals Inc (EYEGW)

Outils de qualité professionnelle, pour des investisseurs individuels.

EYEGW Actualités

EyeGate Pharmaceuticals to Present at the 2016 Aegis Capital Conference

EyeGate Awarded $448,185 for second year of funding of Phase II SBIR Grant from U.S. Department of Defense

EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437

EyeGate Pharmaceuticals to Present at the 18th Annual Rodman and Renshaw Global Investment Conference

EyeGate Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update

EyeGate Announces Positive Top-line Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Post-Operative Inflammat...

EyeGate Announces Completion of $3.77 Million Registered Direct Offering

EyeGate Announces $3.77 Million Registered Direct Offering

EyeGate Announces Encouraging Interim Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Ocular Inflammation an...

EyeGate Pharma Announces At The Market Issuance Program

Eyegate Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update

EyeGate Pharma Appoints Dr. Brenda K. Mann as Vice President, Research and Development

EyeGate Pharma to Present Four Posters at ARVO 2016 Annual Meeting Supporting Development of CMHA-S

EyeGate Pharma Appoints Ryan R. Brenneman as Chief Financial Officer

EyeGate Reports Full-year 2015 Financial Results and Provides Business Update

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Eyegate Pharmaceuticals Inc (EYEGW) Actualités

Eyegate Pharmaceuticals Inc (EYEGW)

Outils de qualité professionnelle, pour des investisseurs individuels.

EYEGW Actualités

EyeGate Pharmaceuticals to Present at the 2016 Aegis Capital Conference

EyeGate Awarded $448,185 for second year of funding of Phase II SBIR Grant from U.S. Department of Defense

EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437

EyeGate Pharmaceuticals to Present at the 18th Annual Rodman and Renshaw Global Investment Conference

EyeGate Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update

EyeGate Announces Positive Top-line Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Post-Operative Inflammat...

EyeGate Announces Completion of $3.77 Million Registered Direct Offering

EyeGate Announces $3.77 Million Registered Direct Offering

EyeGate Announces Encouraging Interim Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Ocular Inflammation an...

EyeGate Pharma Announces At The Market Issuance Program

Eyegate Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update

EyeGate Pharma Appoints Dr. Brenda K. Mann as Vice President, Research and Development

EyeGate Pharma to Present Four Posters at ARVO 2016 Annual Meeting Supporting Development of CMHA-S

EyeGate Pharma Appoints Ryan R. Brenneman as Chief Financial Officer

EyeGate Reports Full-year 2015 Financial Results and Provides Business Update

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application